Central Nervous System Disorders Therapeutics Market Size, Share, Strategies, Insights and Forecasts To 2020

Technavio Announces the Publication of its Research Report Global Central Nervous System (CNS) Disorders Therapeutics Market 2016-2020

Technavio recognizes the following companies as the key players in the global central nervous system (CNS) disorders therapeutics market: GlaxoSmithKline, Pfizer, Eli Lilly, Janssen Pharmaceuticals, and Novartis. 

Browse full report with TOC@ https://marketreportscenter.com/reports/403868/global-central-nervous-system-disorders-therapeutics-market-2016-2020

Other Prominent Vendors in the market are: AB Science, AbbVie, Abital Pharma, Acorda Therapeutics, Active Biotech, Adamas Pharmaceuticals, Addex Therapeutics, Akorn, Alcobra, Alexza Pharmaceuticals, Alkermes, Amarantus, Aprecia Pharmaceuticals, Archer Pharmaceuticals, Astellas, AstraZeneca, Aurobindo Pharma, Auspex Pharmaceuticals, Avanir Pharmaceuticals, Biscayne Pharmaceuticals, Boehringer Ingelheim, Cerecor, Concordia, Convergence Pharmaceuticals, Curemark, CURx Pharmaceuticals, Dainippon Sumitomo Pharma, Dart NeuroScience, Delpor, Desitin Arzneimittel, D-Pharm, Edgemont Pharmaceuticals, Endo International, E-Therapeutics, Euthymics, Evotec, F. Hoffmann-La Roche, Fabre-Kramer Pharmaceuticals, Forum Pharmaceuticals, Gedeon Richter, Glenmark, Grupo Ferrer Internacional, GW Pharmaceuticals, H. Lundbeck, Hisamitsu, Impax, Insero Health, INSYS Therapeutics, Intellipharmaceutics, Intra-Cellular Therapies, Ipsen, Kyowa Hakko Kirin, Ligand Pharmaceuticals, Lupin, MarcoPolo Pharmaceuticals, Marinus Pharmaceuticals, Meda AB, Merck, Mitsubishi Tanabe, MSI Methylation Sciences, Mylan, Naurex, Neuralstem, Neurelis , Neurovance, Nobelpharma, Noven Pharmaceuticals, Omeros, Opexa, Opko Health, Orion, Ophelia Pharmaceutical, Otsuka Pharmaceuticals, Palobiofarma, Par Pharmaceuticals, Pierre Fabre, Pierre Fabre, Prana Biotechnology, Raptor Pharmaceutical, Reviva Pharmaceuticals , SAGE Therapeutics, Sanofi, SciFlour, Sedor Pharmaceuticals, Shire, Siena Biotech, SK Biopharmaceuticals, SOM Biotech, Somerset Pharmaceuticals, STADA Arzneimittel, Sun Pharmaceuticalc, Sunovion Pharmaceuticals, Supernus Pharmaceuticals, Suven, Takeda Pharmaceuticals, Teva Pharmaceuticals, Torrent Pharmaceuticals, Tris Pharma, Turing Pharmaceuticals, UCB, US WorldMeds, Valeant Pharmaceuticals, Zinfandel Pharmaceuticals, and Zogenix.

Commenting on the report, an analyst from Technavios team said: One of the key trends for market growth will be popularity of me-too drugs. Owing to the high cost of development of new drugs, most pharmaceutical companies have been working on developing me-too drugs. A subtle molecular change is carried out in existing compounds to overcome the cost barrier. A me-too drug is a drug with a MOA similar to its predecessor drugs already present in the market. All selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors can be categorized as me-too drugs. Moreover, recently approved drugs for the treatment of depression are generally me-too drugs. Some of the prime examples of me-too drugs are desvenlafaxine (Pristiq), serotonin-norepinephrine reuptake inhibitor, and escitalopram (Lexapro) — a selective serotonin reuptake inhibitor, Pristiq — main metabolite of Effexor and Lexapro, which is the derivative of citalopram (Celexa).”

According to the report, high growth potential of mAbs will be a key driver for market growth. The understanding of a disease at the molecular level increases the development and use of biologics in the treatment. Biologics have a high affinity toward specific disease cells. Biologics account for over 18% of the global pharmaceutical sales, outpacing the sales of branded pharmaceuticals. They will continue to out-perform pharmaceuticals in terms of product sales, as there is an increasing need for effective treatment options. Biologics that treat musculoskeletal disorders are made from proteins. Their MOA is inhibiting the action of key chemicals or cells involved in the nervous system. Few of the mAbs used to treat CNS disorders are natalizumab, daclizumab, and alemtuzumab. Other than these mAbs, many are in various stages of the pipeline for the treatment of CNS disorders.

Further, the report states that the activities of the brain are continuously monitored by RNS system, and when any patterns that could lead to seizures are detected, the neurostimulator sends brief impulses and disrupts the abnormal brain activity. In addition, Medtronic developed Medtronic deep brain stimulation (DBS) therapy as an adjunctive treatment for partial-onset seizures in adults with medically refractory epilepsy. Also, NeuroSigma is under the Phase III development of external trigeminal nerve stimulation (eTNS) for epilepsy, depression, attention deficit hyperactivity disorder (ADHD), post-traumatic stress disorder (PTSD), Lennox-Gastaut syndrome (LGS), and traumatic brain injury (TBI). The rise in research activities in the development of these devices along with their adoption for the treatment of seizures will act as a challenge for the global CNS disorders therapeutics market.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Request A Sample copy of This Report @ https://marketreportscenter.com/request-sample/403868

About CNS disorders

CNS disorders can affect either the brain or spinal cord, or both. CNS disorders are also called as neurological and psychiatric disorders. The major causes of CNS disorders are infections, trauma, degeneration, structural defects, tumors, autoimmune disorders, and stroke. A headache, muscle weakness, memory loss, impaired mental ability, and lack of coordination are few of the symptoms of CNS disorders.

Technavios analysts forecast the global central nervous system (CNS) disorders therapeutics market to grow at a CAGR of 3.38% during the period 2016-2020.

Covered in this report 

The report covers the present scenario and the growth prospects of the global central nervous system (CNS) disorders therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-labeled drugs used for the treatment of various CNS disorders including bipolar disorders, depression, epilepsy, PD, AD, Huntington’s disease (HD), multiple sclerosis (MS), schizophrenia, attention-deficit hyperactivity disorder (ADHD), migraine, and anxiety.

The market is divided into the following segments based on geography: 
Americas
APAC
EMEA

Technavio’s report, Global Central Nervous System (CNS) Disorders Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. 

To Get Discount On The Report @ https://marketreportscenter.com/request-discount/403868

Connect for more details:
Sam Collins
Market Reports Center
1-646-883-3044 (US)
[email protected]